Cargando…
Analytical Validation of an Immunohistochemical 7-Biomarker Prognostic Assay (immunoprint(®)) for Early-Stage Cutaneous Melanoma in Archival Tissue of Patients with AJCC v8 T2–T3 Disease
Selected patients with early-stage melanoma have a “hidden high risk” of poor oncologic outcomes. They might benefit from clinical trials, and ultimately, if warranted by trial results, judicious everyday use of adjuvant therapy. A promising tool to identify these individuals is the immunoprint(®) a...
Autores principales: | Ziemer, Mirjana, Weidenthaler-Barth, Beate, Gussek, Philipp, Pfeiffer, Maja, Kleemann, Johannes, Bankov, Katrin, Wild, Peter J., Seibold, Silke, Sureshkumar, Priyavathi, Nickel, Patricia, Strobel, Anton, Werner, Markus, Grabbe, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572486/ https://www.ncbi.nlm.nih.gov/pubmed/37835839 http://dx.doi.org/10.3390/diagnostics13193096 |
Ejemplares similares
-
Identifying High-Risk Tumors within AJCC Stage IB–III Melanomas Using a Seven-Marker Immunohistochemical Signature
por: Reschke, Robin, et al.
Publicado: (2021) -
Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022) -
AJCC cancer staging manual
Publicado: (1998) -
Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
por: Reschke, Robin, et al.
Publicado: (2021) -
Discriminatory Ability and Clinical Utility of the AJCC7 and AJCC8 Staging Systems for Breast Cancer in a Middle-Income Setting
por: Song, Chin-Vern, et al.
Publicado: (2023)